Neelam Goyal, MD
Neurology · Stanford, CANPI 1558500256
Payments from drug & device makers
Across 306 payments — averaging $1853.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$179K
- Takeda Pharmaceuticals U.S.A., Inc.$99K
- Argenx US, Inc.$98K
- UCB, Inc.$71K
- Amgen$30K
- Johnson & Johnson$26K
- plus $64K from 6 others
Across 3 payments — averaging $5611.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$17K
What the payments were for
- Consulting fees$175,49665%
- Speaking & faculty fees$65,14024%
- Travel & lodging$22,6698%
- Food & beverage$6,9443%
- Education$1100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 71 | $178,799 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $99,179 |
| Argenx US, Inc. | 49 | $97,751 |
| UCB, Inc. | 59 | $71,384 |
| Amgen | 29 | $29,911 |
| Johnson & Johnson(2 entities) | 22 | $26,463 |
| UCB SA | 13 | $25,460 |
| Janssen Scientific Affairs, LLC | 12 | $12,838 |
| Merck Kgaa | 7 | $10,050 |
| Janssen Global Services, LLC | 9 | $7,244 |
| CSL Behring | 8 | $5,177 |
| Novartis Pharma AG | 1 | $3,038 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$567,294 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 48 | $684,518 |
| Mycophenolate Mofetil | 113 | $30,091 |
| Pyridostigmine Bromide | 54 | $3,899 |
| Azathioprine | 16 | $3,053 |
| Prednisone | 124 | $777 |
| Gabapentin | 28 | $725 |
| MethotrexateMethotrexate Sodium | 27 | $518 |
| Duloxetine Hcl | 20 | $137 |
Paid to pharmacies, not to this prescriber.
Other neurology in Stanford
- Timothy CloughesyLos Angeles$33.1M
- Jack FlorinFullerton$13M
- David KudrowSanta Monica$12.8M
- John Ravitsla Jolla$8.4M
- Perminder BhatiaFresno$8.3M
- Perry ShiehLos Angeles$8.2M
- Benjamin FrishbergCarlsbad$8.2M
- Bruce CreeSan Francisco$8M
- Lawrence RechtPalo Alto$6.6M
- Stanley PrusinerSan Francisco$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.